Evidence map›Paper›PMID 27402889›Full record

ArticleNeurology2016

Neuroimaging overuse is more common in Medicare compared with the VA.

James F Burke, Eve A Kerr, Ryan J McCammon, Rob Holleman, Kenneth M Langa, Brian C Callaghan

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

James F BurkeFrom the Department of Neurology (J.F.B., B.C.C.), Department of Internal Medicine (E.A.K., R.J.M., K.M.L.), Institute for Healthcare Policy and Innovation (J.F.B., E.A.K., K.M.L., B.C.C.), and Institute for Social Research (K.M.L.), University of Michigan, Ann Arbor; and Neurology Section (J.F.B., B.C.C.) and Center for Clinical Management and Research (E.A.K., R.H., K.M.L.), VA Ann Arbor Healthcare System, MI. jamesbur@med.umich.edu.
Eve A KerrFrom the Department of Neurology (J.F.B., B.C.C.), Department of Internal Medicine (E.A.K., R.J.M., K.M.L.), Institute for Healthcare Policy and Innovation (J.F.B., E.A.K., K.M.L., B.C.C.), and Institute for Social Research (K.M.L.), University of Michigan, Ann Arbor; and Neurology Section (J.F.B., B.C.C.) and Center for Clinical Management and Research (E.A.K., R.H., K.M.L.), VA Ann Arbor Healthcare System, MI.
Ryan J McCammonFrom the Department of Neurology (J.F.B., B.C.C.), Department of Internal Medicine (E.A.K., R.J.M., K.M.L.), Institute for Healthcare Policy and Innovation (J.F.B., E.A.K., K.M.L., B.C.C.), and Institute for Social Research (K.M.L.), University of Michigan, Ann Arbor; and Neurology Section (J.F.B., B.C.C.) and Center for Clinical Management and Research (E.A.K., R.H., K.M.L.), VA Ann Arbor Healthcare System, MI.
Rob HollemanFrom the Department of Neurology (J.F.B., B.C.C.), Department of Internal Medicine (E.A.K., R.J.M., K.M.L.), Institute for Healthcare Policy and Innovation (J.F.B., E.A.K., K.M.L., B.C.C.), and Institute for Social Research (K.M.L.), University of Michigan, Ann Arbor; and Neurology Section (J.F.B., B.C.C.) and Center for Clinical Management and Research (E.A.K., R.H., K.M.L.), VA Ann Arbor Healthcare System, MI.
Kenneth M LangaFrom the Department of Neurology (J.F.B., B.C.C.), Department of Internal Medicine (E.A.K., R.J.M., K.M.L.), Institute for Healthcare Policy and Innovation (J.F.B., E.A.K., K.M.L., B.C.C.), and Institute for Social Research (K.M.L.), University of Michigan, Ann Arbor; and Neurology Section (J.F.B., B.C.C.) and Center for Clinical Management and Research (E.A.K., R.H., K.M.L.), VA Ann Arbor Healthcare System, MI.
Brian C CallaghanFrom the Department of Neurology (J.F.B., B.C.C.), Department of Internal Medicine (E.A.K., R.J.M., K.M.L.), Institute for Healthcare Policy and Innovation (J.F.B., E.A.K., K.M.L., B.C.C.), and Institute for Social Research (K.M.L.), University of Michigan, Ann Arbor; and Neurology Section (J.F.B., B.C.C.) and Center for Clinical Management and Research (E.A.K., R.H., K.M.L.), VA Ann Arbor Healthcare System, MI.
VA Center for Clinical Management Research · US

Funding

HRS Yrs29-34: Y33 SSA CoFundingU01AG009740 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jessica Faul, KENNETH M LANGA · 1990 to 2026
$555.8M
UNDERSTANDING SOCIAL DISPARITIES IN HEALTH AND AGINGR01AG018418 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BURGARD, SARAH A. · 2000 to 2015
$6.3M
The Cost of DementiaR01AG030155 · NIA · RAND CORPORATION · PI HURD, MICHAEL D · 2007 to 2011
$3.1M
AHRQ HHS R01 HS018334AHRQ HHS R01 HS021681HSRD VA I01 HX001276NIA NIH HHS R01 AG018418NIA NIH HHS R01 AG030155NIA NIH HHS U01 AG009740
6 · The paper itself

Abstract

objectiveTo inform initiatives to reduce overuse, we compared neuroimaging appropriateness in a large Medicare cohort with a Department of Veterans Affairs (VA) cohort.

methodsSeparate retrospective cohorts were established in Medicare and in VA for headache and neuropathy from 2004 to 2011. The Medicare cohorts included all patients enrolled in the Health and Retirement Study (HRS) with linked Medicare claims (HRS-Medicare; n = 1,244 for headache and 998 for neuropathy). The VA cohorts included all patients receiving services in the VA (n = 93,755 for headache and 183,642 for neuropathy). Inclusion criteria were age over 65 years and an outpatient visit for incident neuropathy or a primary headache. Neuroimaging use was measured with Current Procedural Terminology codes and potential overuse was defined using published criteria for use with administrative data. Increasingly specific appropriateness criteria excluded nontarget conditions for which neuroimaging may be appropriate.

resultsFor both peripheral neuropathy and headache, potentially inappropriate imaging was more common in HRS-Medicare compared with the VA. Forty-nine percentage of all headache patients received neuroimaging in HRS-Medicare compared with 22.1% in the VA (p < 0.001) and differences persist when analyzing more specific definitions of overuse. A total of 23.7% of all HRS-Medicare incident neuropathy patients received neuroimaging compared with 9.0% in the VA (p < 0.001), and the difference persisted after excluding nontarget conditions.

conclusionsOveruse of neuroimaging is likely less common in the VA than in a Medicare population. Better understanding the reasons for the more selective use of neuroimaging in the VA could help inform future initiatives to reduce overuse of diagnostic testing.

Indexed as

AgedAged, 80 and overCohort StudiesFemaleHeadache Disorders, PrimaryHumansMaleMedicareNeuroimagingPeripheral Nervous System DiseasesUnited StatesUnited States Department of Veterans AffairsUnnecessary Procedures

Identifiers

PMID27402889
PMCPMC4999324
OpenAlexW2465956380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.